Literature DB >> 28620779

The cost of a patient activation intervention for achieving successful outcomes: results from the PAADRN randomized controlled trial.

F D Wolinsky1,2,3, S F Hall4, Y Lou5, S W Edmonds4,6,7, K G Saag8, D W Roblin9,10, N C Wright8,11, M P Jones5, P Cram4,12,13, J R Curtis, S L Morgan, J A Schlechte, J H Williams, D J Zelman.   

Abstract

In a large, pragmatic clinical trial, we calculated the costs of achieving four successful patient-centered outcomes using a tailored patient activation DXA result letter accompanied by a bone health brochure. The cost to achieve one successful outcome (e.g., a 0.5 standard deviation improvement in care satisfaction) ranged from $127.41 to $222.75.
INTRODUCTION: Pragmatic randomized controlled trials (RCTs) should focus on patient-centered outcomes and report the costs for achieving those outcomes. We calculated per person incremental intervention costs, the number-needed-to-treat (NNT), and incremental per patient costs (cost per NNT) for four patient-centered outcomes in a direct-to-patient bone healthcare intervention.
METHODS: The Patient Activation after DXA Result Notification (PAADRN) pragmatic RCT enrolled 7749 patients presenting for DXA at three health centers between February 2012 and August 2014. Interviews occurred at baseline and 52 weeks post-DXA. Intervention subjects received an individually tailored DXA result letter accompanied by an educational bone health brochure 4 weeks post-DXA, while the usual care subjects did not. Outcomes focused on patients (a) correctly identifying their results, (b) contacting their providers, (c) discussing their results with their providers, and (d) satisfaction with their bone healthcare. NNTs were determined using intention-to-treat linear probability models, per person incremental intervention costs were calculated, and costs per NNT were computed.
RESULTS: Mean age was 66.6 years old, 83.8% were women, and 75.3% were non-Hispanic whites. The incremental per patient cost (costs per NNT) to increase the ability of a patient to (a) correctly identify their DXA result was $171.07; (b) contact their provider about their DXA result was $222.75; (c) discuss their DXA result with their provider was $193.55; and (d) achieve a 0.5 SD improvement in satisfaction with their bone healthcare was $127.41.
CONCLUSION: An individually tailored DXA result letter accompanied by an educational brochure can improve four patient-centered outcomes at a modest cost. TRIAL REGISTRATION: clinicaltrials.gov identifier NCT01507662.

Entities:  

Keywords:  Clinical trials; Costs; DXA; Osteoporosis; Patient activation

Mesh:

Year:  2017        PMID: 28620779      PMCID: PMC5670012          DOI: 10.1007/s00198-017-4113-1

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  19 in total

1.  A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers.

Authors:  Kevin E Thorpe; Merrick Zwarenstein; Andrew D Oxman; Shaun Treweek; Curt D Furberg; Douglas G Altman; Sean Tunis; Eduardo Bergel; Ian Harvey; David J Magid; Kalipso Chalkidou
Journal:  J Clin Epidemiol       Date:  2009-05       Impact factor: 6.437

2.  Efficacy, effectiveness, pragmatic trials--guidance on terminology and the advantages of pragmatic trials.

Authors:  Claudia M Witt
Journal:  Forsch Komplementmed       Date:  2009-08-25

3.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

4.  An estimate of the worldwide prevalence and disability associated with osteoporotic fractures.

Authors:  O Johnell; J A Kanis
Journal:  Osteoporos Int       Date:  2006-09-16       Impact factor: 4.507

5.  The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine.

Authors:  Nicole C Wright; Anne C Looker; Kenneth G Saag; Jeffrey R Curtis; Elizabeth S Delzell; Susan Randall; Bess Dawson-Hughes
Journal:  J Bone Miner Res       Date:  2014-11       Impact factor: 6.741

6.  The PAADRN study: a design for a randomized controlled practical clinical trial to improve bone health.

Authors:  Stephanie W Edmonds; Fredric D Wolinsky; Alan J Christensen; Xin Lu; Michael P Jones; Douglas W Roblin; Kenneth G Saag; Peter Cram
Journal:  Contemp Clin Trials       Date:  2012-10-17       Impact factor: 2.226

7.  Pragmatic Trials.

Authors:  Ian Ford; John Norrie
Journal:  N Engl J Med       Date:  2016-08-04       Impact factor: 91.245

8.  Clinician's Guide to Prevention and Treatment of Osteoporosis.

Authors:  F Cosman; S J de Beur; M S LeBoff; E M Lewiecki; B Tanner; S Randall; R Lindsay
Journal:  Osteoporos Int       Date:  2014-08-15       Impact factor: 4.507

9.  Developing a bone mineral density test result letter to send to patients: a mixed-methods study.

Authors:  Stephanie W Edmonds; Samantha L Solimeo; Xin Lu; Douglas W Roblin; Kenneth G Saag; Peter Cram
Journal:  Patient Prefer Adherence       Date:  2014-06-05       Impact factor: 2.711

10.  Effects of a DXA result letter on satisfaction, quality of life, and osteoporosis knowledge: a randomized controlled trial.

Authors:  Stephanie W Edmonds; Peter Cram; Yiyue Lou; Michael P Jones; Douglas W Roblin; Kenneth G Saag; Nicole C Wright; Fredric D Wolinsky
Journal:  BMC Musculoskelet Disord       Date:  2016-08-26       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.